In the course of our screening program for antitumor compoundsfrom microbial fermentatioi products, FR900840 was discovered in the culture broth of Streptomyces strain No. 87271}. Thi chemical structure of FR900840 was determined on the basis of chemical and spectroscopic evidences as shown in Fig. 1 . The structural elucidations of this compoundare reported in a separate paper2).
In this paper we describe the taxonomy of the producing strain, fermentation and isolation procedures and some physico-chemical and biological properties of FR900840. 
Materials and Methods

Taxonomic Study
The methods described by Shirling and Gottlieb3) were employed principally for this taxonomic study.
Morphological observations were madewith light and electron microscopes from cultures grown at 30°C for 21 days on yeast extract -malt extract agar, inorganic salts -starch agar, oatmeal agar and glucose -asparagine agar.
Cell wall analysis was performed by the methods of Becker et a!.*\ and Yamaguchi5). Temperature range for growth was determined on yeast extract -malt extract agar using a model TN-3 temperature gradient incubator (Toyo Kagaku Sangyo Co., Ltd.).
Utilization of carbon sources was examined according to the method of Pridham and Gottlieb6:). The results were determined after 14 days incubation at 30°C.
Ferment at i on A culture medium 100 ml containing corn starch 1 %, glycerol 1 %, glucose 0.5 %, Pharmamedia 0.5%, dried yeast 0.5%, corn steep liquor 0.5% and calcium carbonate 0.2% at pH 6.5 was poured into a 500-ml Erlenmeyer flask and sterilized at 120°C for 30 minutes. The medium was inoculated with a loopful of slant culture of Streptomyces sp. No. 8727 and incubated at 30°C for 3 days on a rotary shaker. The resultant culture was inoculated into 150 liters of a mediumcontaining soluble starch 2%, corn starch 1 %, Pharmamedia 1 %, corn steep liquor 0.5%, dried yeast 0.1 %, NaCl 0.1 %, MgSO4-7H2O 0.05%, CaCO3 0.2%, Adekanol (defoaming agent; Asahi Denka Co., Ltd.) 0.1 % 543 in a 200-liter jar fermentor, which had been sterilized at 120°C for 30 minutes. This was cultured at 30°C for 4 days with aeration of 100 liters/minute and with agitation at 200 rpm.
Tumor Cell Lines and Culture Conditions Mouseleukemia P388, humanlung adenocarcinoma A549 and humanmammaryadenocarcinoma MCF-7 were used for the experiments. Tumorcells were cultured at 37°Cin a humidified atomosphere of 5% CO2-95% air in each medium. RPMI1640 medium was used for P388, Dulbecco's minimum essential mediumwas used for A549 and Eagle's minimumessential mediumsupplemented with sodium pyruvate and nonessential amino acids was used for MCF-7. Benzylpenicillin (50 u/ml), streptomycin (50^g/ml) and 10% fetal calf serum were supplemented in all medium. Antitumor Activity (In Vitro)
In vitro antitumor activities were tested in microtiter plates, with each well containing 3 x 103 tumor cells in 100 /jI medium. The cells were incubated at 37°C for 7 days and the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2#-tetrazolium bromide (MTT) assay was performed according to the method described by Mosmann7). Briefly, MTTwas dissolved in phosphate buffered saline at 5 mg/ml and filtered to sterilize and remove a small amount of insoluble residue. After the culture was terminated, this MTTsolution (10 jul per 100 fi\ medium) was added to all wells, and the plates were further incubated at 37°C for 4 hours. Acid -2-propanol (100 [A of 0.04 n HC1in 2-propanol) was added to all wells and mixed thoroughly to dissolve the dark blue crystals. After all crystals were dissolved, the plates were read on a 2-wavelength microplate photometer (Model MTP-22; Corona Electric Co., Ltd.) at 550 nm, a reference wavelength of 660 nm. FR900840 was dissolved in the mediumand added to the culture to give final concentration of 100^g/ml or less.
Subrenal Capsule (SRC) Assay Weestablished a 2-week SRCassay by using an immunosuppressive agent FK-506 which was developed in our Research Laboratories83. A precise report of this SRCassay will be published elsewhere. In brief, a 1-mm3tumor fragment was implanted under kidney capsule at day-0. FR900840 was dissolved in phosphate buffered saline and was injected ip at day-1, 5 and 9. Fourteen days after tumor implantation, the length and width of tumors were measured by caliper and tumor volumewas calculated by the following formula :
where (a) represents the length and (b) represents the width.
Animals
Female mice of BDFi strain were purchased from Charles River Japan Inc., Atsugi-city, Japan and were used for the SRCassay.
Results
Taxonomy of Strain No. 8727 Strain No. 8727 was isolated from a soil sample obtained from Ishioka-city, Ibaragi Prefecture, Japan.
The branching type of sporophores was monopodial; the form of mature sporophores was Spira with 20 to 70 spores in each chain. The spores were determined by electron microscopy to be oval and measured 0.6~0.7x0.9~l.l^m in size. The spore surface was spiny (Fig. 2) . Neither fragmentation of hyphae nor formation of spores occurred in the substrate mycelium. Sporangia, sclerotia and zoo-spores were not observed. Analysis of whole cell hydrolysates showed the presence of LL-diaminopimelic acid. Accordingly the cell wall of this strain is classified as type I.
Summarized physiological properties of strain No. 8727 were shown in Table 1 . The tempera- ture range for growth was from 13 to 37°C with optimum temperature from 30 to 32°C. Milk peptonization and gelatin liquefaction were positive. Production of melanoid pigment was positive on tyrosine agar.
This strain could utilize all carbon sources tested for growth as shown in Table 2 .
As Ferment at i o n The time course of FR900840 production by Streptomyces sp. No. 8727 in a 200-liter jar fermentor is shown in Fig. 3 . The organism reached the stationary phase of growth after a 72-hour incubation. FR900840production began at 24 hours, and the maximumaccumulation was observed after a 96-hour incubation period.
Isolation Procedure
The flow diagram of the isolation procedure described below is shown in Fig. 4 . The culture broth was filtered with the aid of diatomaceous earth (5 kg). The filtrate (110 liters) was adjusted to pH 7.0 and passed through a column of active carbon (10 liters). After washing with water (30 liters), elution was carried out with 5 %aqueous acetone (30 liters). The eluate was evaporated under reduced pressure to give an oily residue. The oily residue was mixed with 500 g of silica gel (70~230 mesh, Merck Co., Ltd., U.S.A.), and this mixture was slurried in methanol. After the solvent was evaporated, the resultant dry powder was subjected to column chromatography of the same silica gel (1.5 liters) which was packed with a mixture of chloroform, methanol and water (10 : 6 : 1). The column was developed with the same solvent system. Fractions containing FR900840were collected and concentrated under reduced pressure to give FR900840 in the form of pale yellowish oil. This oil was dissolved in ethanol and concentrated under reduced pressure. This concentrate was kept at room temperature and purified FR900840 substance (15 g) was obtained as pale yellowish prisms.
Physico-chemical
Properties of FR900840 Physico-chemical properties of FR900840 are summarized in Table 3 . It is insoluble in acetone, APR. 1989 chloroform, ethyl acetate, diethyl ether and benzene. It is sparingly soluble in methanol, ethanol and soluble in water. Color reactions are as follows : Positive in eerie sulfate, sulfuric acid, ninhydrin, ferric chloride and iodine vapor tests, and negative in Ehrlich, Dragendorff and Molisch tests. Its Rf value on silica gel TLCdeveloped with a mixture of butanol, ethanol, chloroform and aqueous ammonia (2 : 1 : 1 :2) was 0.44. The determination of the chemical structure of FR900840 will be described in the succeeding paper2).
Biological Properties of FR900840
Antimicrobial Activities
The antimicrobial activities shown in Table 4 . FR900840 showed week antifungal activity against Geotrichum candidum. It had no inhibitory effect on bacteria, Candida albicans, Aspergillus niger and Aureobasidium pullulans at 1 ,000^g/ml.
Antitumor Activity (In Vitro)
In vitro antitumor activities are shown in Table 5 . FR900840 had almost equal in vitro antitumor activity against human lung adenocarcinoma A549 and human mammaryadenocarcinoma MCF-7. The IC50 value (the concentration causing 50% inhibition) for the two tumor lines were 0.50 and 0.55^g/ml, respectively. It showed a comparatively weak growth inhibitory effect on mouse leukemia P388. Its IC50 value was 33^g/ml.
Antitumor Activity in Mice
Antitumor activity of FR900840 was examined against two kinds of human tumors, A549 and MCF-7, implanted under the kidney capsule of immunosuppressed BDFi mice (SRC assay). Tumor volume was measured on day-14. The MICwas expressed in terms of^g/ml after overnight incubation at 37°C for bacteria and 487 2 hours incubation at 28°C for fungi and yeasts. Tumor cells (P388; 2x lO3/well, MCF-7 and A549; 3 x lO3/well) were incubated with FR900840 at 37°C for 7 days, and colorimetric MTTassay was performed. OD550represent the average OD550 value± SE of 5 wells. a Body weight change was calculated from the body weights of day-0 and 14. b A 1-mm3tumor fragment was implanted under the renal capsule ofBDFi mouse at day-0 and FR900840 was injected ip at day-1, 5 and 9. The final tumor size was measured at day-14. The tumor volume is indicated by meandbSE. a»b Experimental conditions were the same as for Table 6 .
As shown in Tables 6 and 7 , ip injection of FR900840 inhibited growth of human tumors, A549 and MCF-7. The volume of both tumors decreased by more than 70%at dose of 32 mg/kg. Acute Toxicity
The LD50 values of FR900840 when given intraperitoneally and intravenously to BDFi mice were 290 and 320 mg/kg, respectively. Discussion P388 mouse leukemia cell was widely used for a long time as a model for screening of antitumor compounds by the National Cancer Institute (NCI) and was believed to give good correlation between animal and clinical effects of known antitumor drugs12). However, there is still a"need for a more reliable screening method which would predict the clinical effect of novel antitumor compound150. For this reason, we have searched for novel products from fermentation broths which would shown a specific inhibitory effect on the growth of humantumor cells, and not on the growth of P388 mouse leukemia cells.
As a result of screening, we isolated a novel antibiotic, FR900840, from the culture broth of Streptomyces sp. No. 8727. It was a pale yellowish prism which was soluble in water, and which was found to have a novel structure as shown in Fig. 1 . Details on the structural elucidations will be published in the succeeding paper2). This compoundwas found to be unstable in acidic solution (unpublished data). Wedissolved it in the culture mediumor phosphate buffered saline to examine its biological activities. FR900840 showed growth inhibitory effects on human solid tumor lines in vitro, and IC50 values for them were less than 1/50 for mouse leukemia P388. Moreover FR900840 had potent antitumor activities against the two humansolid tumors in vivo.
Precise antitumor activity of this novel compoundwill be reported in a separate paper14).
